ACIP Dengue Vaccine Workgroup

Katherine A. Poehling, MD, MPH
Wilbur Chen, MD, MSc
ACIP Members and Workgroup Co-Chairs
Advisory Committee on Immunization Practices
ACIP Meeting February 24, 2021
# ACIP Dengue Vaccines Workgroup

<table>
<thead>
<tr>
<th><strong>ACIP Members</strong></th>
<th><strong>Liaison Representatives</strong></th>
<th><strong>CDC Contributors</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Kathy Poehling (Co-chair)</td>
<td>Elizabeth Barnett (AAP)</td>
<td>Anita Shet</td>
</tr>
<tr>
<td>Wilbur Chen (Co-Chair)</td>
<td>Rob Schechter (AIM)</td>
<td>Steve Waterman</td>
</tr>
<tr>
<td>Beth Bell</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Veronica McNally</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ex Officio Members</strong></th>
<th><strong>Consultants</strong></th>
<th><strong>Others</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaitlyn Morabito (NIH)</td>
<td>Edwin Asturias</td>
<td>Laura Adams</td>
</tr>
<tr>
<td>Ralph LeBlanc (FDA)</td>
<td>Robert Atmar</td>
<td>Mimi Eckert</td>
</tr>
<tr>
<td>Kirk Prutzman (FDA)</td>
<td>Alan Barrett</td>
<td>Rachel Eidex</td>
</tr>
<tr>
<td>Srihari Seshadri (DOD)</td>
<td>Anna Durbin</td>
<td>Susan Hills</td>
</tr>
<tr>
<td></td>
<td>Ines Esquilin</td>
<td>Terri Hyde</td>
</tr>
<tr>
<td></td>
<td>Tony Marfin</td>
<td>Mike McNeil</td>
</tr>
<tr>
<td></td>
<td>Hal Margolis</td>
<td>Jorge Munoz</td>
</tr>
<tr>
<td></td>
<td>Kristen Pierce</td>
<td>Erin Staples</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cindy Weinbaum</td>
</tr>
</tbody>
</table>
Dengue vaccine workgroup timeline

2017
Dengue epi and vaccine development

2018
WG on hold
Flavivirus WG split
Dengue Vaccine Workgroup is formed

2019
Phase 3 results
Safety & pharmacovigilance
GRADE
Cost effectiveness
Dengue Diagnostics
Partially effective vaccines
Dengue vaccine in Philippines
VRBPAC review
FDA approval

2020
Vaccine acceptability
WHO global position
Feasibility
Health Equity

2021
Dengue IgG test evaluation
Evidence to recommendations framework (EtR)
Draft recommendations to ACIP
Dengue Vaccine Workgroup Discussions
Nov 2020-Feb 2021

• Zika virus infection enhances future risk of severe dengue disease – Lea Katzelnick, UC Berkley
• Update on development status of a new dengue IgG rapid test to determine past infection – Stephen Savarino, Sanofi
• Feasibility of CYD-TDV vaccination program – Steve Waterman, CDC
• CYD-TDV and Health Equity -Laura Adams, CDC
• Evaluation of commercial dengue IgG tests – Freddy Medina, CDC
• Straw poll and discussion on evidence to recommendations sections – Gabriela Paz-Bailey
Importance of a specific test for pre-vaccination screening

• CYD-TCV vaccine presents novel challenges due to requirement of pre-vaccination screening

• A test for pre-vaccination dengue screening needs to be specific to minimize vaccination of seronegative children and sensitive to maximize identification of children who can benefit from the vaccine

• The workgroup is reviewing data and considering including recommended test performance characteristics in the MMWR accompanying future ACIP recommendations
Anticipated ACIP Schedule 2021

• Further workgroup discussions to finalize the evidence to recommendations framework (EtR)

• ACIP Spring 2021 Meeting
  • EtR and draft WG recommendations

• ACIP June 2021 Meeting
  • ACIP vote CYD TDV recommendations
Presentation

Evaluation of Commercial Dengue Virus IgG Tests for Pre-vaccination Screening

Freddy Medina, PhD
Immunodiagnostic Activity Lead
Dengue Branch Surveillance and Research Laboratory
Centers for Disease Control and Prevention
Feedback

• Are there other considerations the workgroup should address?